Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

Ovejero-Benito Maria C.; Prieto-Perez Rocio; Llamas-Velasco Mar; Belmonte Carmen; Cabaleiro Teresa; Roman Manuel; Ochoa Dolores; Talegon Maria; Saiz-Rodriguez Miriam; Dauden Esteban; Abad-Santos Francisco

首页> 外文期刊>Pharmacogenomics >Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

【24h】

Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

机译：与中度至重度斑块牛皮癣相关的多态性与依赖氏菌反应相关的多态性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept. Materials & methods: We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68). Results: The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months. Besides polymorphisms rs928655 (GBP6) and rs2546890 (IL12B) were associated to response at 6 months. Conclusions. Nevertheless, these biomarkers should be validated in large-scale studies before its implementation in clinical practice.

机译：目的：少数研究评估了药物生物原理在用依赖替埃沙尼普治疗的银屑病患者的影响。材料和方法：我们在3个月（n = 78）和6个月的治疗中（n = 68）的中度至重度斑块牛皮癣患者的患者对124种多态性之间的关联评估了124种多态性之间的关联。结果：多变量分析结果显示多态性RS13437088（HLA-B / MICA），RS96844（MAP3K1），RS2431697（PTTG1），RS9304742（ZNF816A）的响应与3个月的响应。除了多态性RS928655（GBP6）和RS2546890（IL12B）之外，与6个月相关响应。结论。然而，在临床实践中实施之前，这些生物标志物应在大规模研究中验证。

著录项

来源
《Pharmacogenomics》 |2017年第7期|共8页
作者
Ovejero-Benito Maria C.; Prieto-Perez Rocio; Llamas-Velasco Mar; Belmonte Carmen; Cabaleiro Teresa; Roman Manuel; Ochoa Dolores; Talegon Maria; Saiz-Rodriguez Miriam; Dauden Esteban; Abad-Santos Francisco;
展开▼
作者单位

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Dermatol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Madrid Spain;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

UAM Dermatol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Madrid Spain;

UAM Clin Pharmacol Dept Inst Invest Sanitaria La Princesa IIS IP Hosp Univ Princesa Inst Teofilo;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
etanercept; pharmacogenetics; psoriasis;

机译：Etanercept;药物遗传学;牛皮癣;

相似文献

外文文献
中文文献
专利

1. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis (vol 18, pg 631, 2017) [J] . Ovejero-Benito Maria C., Prieto-Perez Rocio, Llamas-Velasco Mar, Pharmacogenomics . 2018,第7期

机译：与中度至重度斑块牛皮癣（Vol 18，PG 631,2017）中的依赖替涅氏响应相关的多态性
2. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis [J] . Ovejero-Benito Maria C., Prieto-Perez Rocio, Llamas-Velasco Mar, Pharmacogenomics . 2017,第7期

机译：与中度至重度斑块牛皮癣相关的多态性与依赖氏菌反应相关的多态性
3. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study [J] . de Vries A. C. Q., Thio H. B., de Kort W. J. A., British Journal of Dermatology . 2017,第3期

机译：比较inciximab和依赖啶患者中度至重度慢性噬斑型牛皮癣患者的前瞻性随机对照试验：牛皮癣inciximab与依赖替辛比较评价（件）研究
4. A gold nanoparticles-based colorimetric test to detect single nucleotide polymorphisms for improvement of personalized therapy of psoriasis [C] . Alessandra Marsella, Paola Valentini, Paolo Tarantino, SPIE Conference on Biophotonics . 2016

机译：基于金纳米颗粒的比色试验检测单核苷酸多态性，以改善牛皮癣的个性化治疗
5. The impact of pruritus on the health-related quality of life of patients with chronic plaque psoriasis [D] . Majeski, Candace Julie Ann 2006

机译：瘙痒对慢性斑块牛皮癣患者健康有关质量的影响
6. Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) [O] . Andrew Blauvelt, Kim A. Papp, Christopher E. M. Griffiths, -1

机译：校正至：在Etanercept非应答者中改用伊克珠单抗的疗效和安全性：中度至重度斑块状牛皮癣的两个III期随机临床试验的亚分析（UNCOVER-2和-3）
7. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes [O] . L Puig, M Dossenbach, L Berggren, 2019

机译：绝对和相对牛皮癣区域和严重程度指数（PASI），用于比较Ixekizumab与中度至严重的斑块牛皮癣患者依赖伊沙康和安慰剂的疗效：对揭露-2和未发现的3个结果的综合分析

Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

摘要

著录项

相似文献

相关主题

期刊订阅